Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Alembic site hit with warning letter on patient consent concerns
After a March inspection yielded a Form 483, Indian generics juggernaut Alembic has received a harsher reprimand from the FDA.
Fraiser Kansteiner
Jul 21, 2026 11:40am
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Jul 21, 2026 10:36am
Operating at the speed of science: The new medical affairs playbook
Brought to you by
ZS
Gilead, Merck phase 3 data back first weekly HIV pill
Jul 21, 2026 10:00am
Access: A key driver of non-opioid pain management adoption
Brought to you by
Pacira BioSciences, Inc.
Novo accuses Lilly of running ‘false and misleading’ GLP-1 ads
Jul 21, 2026 9:18am
